Our Analysis·May 30, 2026·12 min read

What ClearNote Health’s $52M Series D Signals for Blood-Based Early Cancer Detection

A pragmatic cancer-screening round built around high-risk pancreatic detection, 82.6% sensitivity, 97.5% specificity, and a category that is becoming more fundable but less forgiving.

Context

On May 27, 2026, ClearNote Health announced a $52M Series D to accelerate early cancer detection. The company says total funding now exceeds $185M. The round follows a cluster of de-risking events: New York State Department of Health approval for Avantect Pancreatic Cancer Test in February 2025, UKCA marking for Avantect Pancreatic in July 2025, UK in vitro diagnostic approval for Avantect MCD and Ovarian in September 2025, and selection of Avantect MCD for the NCI Vanguard Study in January 2025.

The thesis is not that everyone will soon get screened for every cancer with one blood draw. ClearNote’s sharper wedge is high-risk, clinically actionable screening for cancers where late diagnosis is deadly and existing screening is weak. Its pancreatic test targets elevated-risk groups such as patients with genetic predisposition, family history, or people age 50+ newly diagnosed with type 2 diabetes. That is a much cleaner story for physicians, payers, and investors than broad general-population MCED.

The evidence package is the heart of the round. ClearNote reported 82.6% overall sensitivity, 76.8% sensitivity for early-stage Stage I-II pancreatic cancer, and 97.5% specificity in a 1,445-person independent validation cohort of high-risk individuals. In diagnostics, that specificity number matters because it determines whether the test creates manageable clinical value or overwhelms the system with false positives, anxiety, imaging, and follow-up procedures.

The tension is that blood-based early cancer detection is investable again, but only under stricter rules. Broad MCED still faces hard questions around reimbursement, mortality benefit, follow-up pathways, false positives, and clinical utility. ClearNote’s round says investors may prefer narrower, painful, high-unmet-need wedges that can move into clinical workflow faster. The bet is less grandiose than the biggest MCED visions, but that is why it looks more commercially intelligent.

Q1What are some interesting signals regarding the size of ClearNote Health’s Series D round?

ClearNote Health’s $52M Series D is a serious round, but it is not a category-dominating round. It puts ClearNote in the top tier of recent private blood-based early cancer detection challengers without making it the best-funded player.

Against direct competitors, ClearNote’s $52M Series D ranks fifth if public-company and older competitor financings are included. Larger rounds include GRAIL’s $325M PIPE in October 2025, Freenome’s $254M financing in February 2024, Harbinger Health’s $100M financing announced in April 2026, and Mercy BioAnalytics’ $59M Series B in September 2025. So no, this is not the largest direct-competitor round.

The more relevant private-market comparison is cleaner. Excluding GRAIL’s public PIPE and Freenome’s older February 2024 financing, ClearNote ranks third among recent private-style category rounds, behind Harbinger’s $100M and Mercy’s $59M. That is a respectable position. It means ClearNote is not outspending the category, but it is absolutely in the serious-company bracket.

The round is 52% of Harbinger’s $100M financing and 88% of Mercy’s $59M Series B. It is also 1.53x PrognomiQ’s $34M Series D and roughly 4.7x OXcan’s $11M Series A. Those ratios are useful because they show ClearNote sitting between the biggest platform bets and the smaller single-cancer or earlier-stage challengers.

For more data on this, please check full memo.

Versus the median latest round of the direct-competitor set, ClearNote is almost exactly in the middle. The median latest-round amount is roughly $55.5M, and ClearNote’s $52M is about 0.94x that median. The round size itself is not extraordinary. The real story is that ClearNote raised a median-sized competitor round after accumulating above-average validation and access signals.

The round is also not one of the biggest financings across all industries recently. That context should be ignored in the article unless the goal is to explicitly say ClearNote is not a mega-round story. The useful framing is sector-specific: this is a credible late-stage diagnostics commercialization round in a category where capital is concentrated and adoption risk is high.

The smart interpretation is that ClearNote raised enough to matter without turning the company into a hype-financed platform bet. That fits the company’s strategy. ClearNote does not need to outspend GRAIL or Freenome if its high-risk pancreatic wedge can win faster through clearer patient selection, stronger payer logic, and a more defined physician workflow.

Evidence noteRound-size comparisons use disclosed financing amounts from the retained blood-based early cancer detection competitor set. Public-company style financings and older rounds are shown for context, while the cleaner private-market ranking excludes GRAIL’s PIPE and Freenome’s older February 2024 financing. Ratios are calculated from disclosed round amounts. See methodology below.

Q2How well-funded is ClearNote Health today compared with its competitors?

ClearNote Health is well-funded enough to be a serious challenger, but it is not funded like the category giants. Its position is mid-to-upper tier, with a stronger capital-efficiency story than a capital-dominance story.

ClearNote says total funding now exceeds $185M after the $52M Series D. That puts it below GRAIL, Freenome, DELFI Diagnostics, and Harbinger Health, but above PrognomiQ, Mercy BioAnalytics, and OXcan. In the direct-competitor set, ClearNote ranks around fifth by cumulative funding if GRAIL is included and Exact Sciences is excluded as a public-company outlier.

The gap to the biggest players remains massive. GRAIL has roughly $2.0B in total funding, more than 10x ClearNote. Freenome has roughly $1.35B, more than 7x ClearNote. DELFI Diagnostics has around $333M to $365M, roughly 1.8x to 2.0x ClearNote. Harbinger Health has around $290M, roughly 1.6x ClearNote.

The Series D still changed ClearNote’s position. Before the round, ClearNote had roughly more than $133M in cumulative funding, inferred from more than $185M after the round minus $52M. After the round, it moved ahead of PrognomiQ and further ahead of Mercy BioAnalytics. The company is now clearly more heavily funded than the smaller private challengers, but still far behind the most capitalized platforms.

We go deeper on this point in our latest market report.

On capital velocity, ClearNote is not the aggressive raiser in the category. Founded around 2016, the company has raised more than $185M over about 10 years, or more than $18.5M per year. That is far below GRAIL at roughly $200M per year, Freenome at roughly $113M per year, DELFI at roughly $52M per year, and Harbinger at roughly $48M per year. It is closer to Mercy BioAnalytics, which has raised around $127M since 2018, or roughly $16M per year.

This is where ClearNote’s case gets more interesting. The company’s story is not “we raised the most.” It is “we got meaningful validation, regulatory progress, institutional study selection, payer signals, and senior commercial leadership without needing the most capital in the category.” That is a better story than just being overfunded.

The funding cadence has also accelerated recently. The known sequence is a $70M Series C in May 2021, a roughly $21.8M equity filing in June 2025, and the $52M Series D in May 2026. The gap from the 2021 Series C to the June 2025 filing was about 49 months. The gap from the June 2025 filing to the May 2026 Series D was about 12 months. The latest round is also about 2.4x larger than the June 2025 filing amount.

That pattern suggests the company spent years building evidence before raising for scale. It did not behave like a company constantly refilling the tank around a vague platform story. It looks more like a company whose fundraising intensity increased once the commercial case became easier to defend.

Evidence noteCumulative funding comparisons use company-reported totals where available and secondary funding databases or filings where direct company totals are incomplete. ClearNote’s pre-Series D funding is inferred from its disclosed post-round total of more than $185M minus the $52M Series D, so that figure should be read as an approximate lower bound. See methodology below.

Q3What is the current funding activity in the blood-based early cancer detection diagnostics category?

Funding activity in blood-based early cancer detection diagnostics is picking up, but the market is still small, concentrated, and extremely lumpy.

In the last six months, four companies in the category raised financing: ClearNote Health, Harbinger Health, DELFI Diagnostics, and Cyclomics. In the last 12 months, six companies raised: ClearNote Health, Harbinger Health, DELFI Diagnostics, Cyclomics, GRAIL, and Mercy BioAnalytics. In the last 24 months, eight companies raised: ClearNote Health, Harbinger Health, DELFI Diagnostics, Cyclomics, GRAIL, Mercy BioAnalytics, OXcan, and PrognomiQ.

Capital raised in the category reached roughly $189.3M in the last six months, $573.3M in the last 12 months, and $618.3M in the last 24 months. These totals include GRAIL’s $325M public-company PIPE and DELFI’s $34.33M debt financing because both are real financing events in the category, even if they are not classic private VC rounds.

ClearNote captured about 8.4% of the roughly $618.3M raised in the category over the last 24 months. That makes it the fourth-largest capital recipient in the period. GRAIL ranked first with $325M, or about 52.6% of 24-month category capital. Harbinger ranked second with $100M, or about 16.2%. Mercy BioAnalytics ranked third with $59M, or about 9.5%. ClearNote followed with $52M, or about 8.4%.

It’s actually something we elaborate on in our latest market report.

The category is heavily concentrated. GRAIL alone captured about 52.6% of all counted 24-month category capital. The top three companies, GRAIL, Harbinger Health, and Mercy BioAnalytics, captured about 78.3%. Even if GRAIL is excluded because its financing is public-company style, the private challenger market is still concentrated around Harbinger, Mercy, and ClearNote.

Deal activity is clearly accelerating. The last six months had four deals versus two in the previous six months, a 2.0x increase. The last 12 months had six deals versus two in the previous 12 months, a 3.0x increase. More companies are getting funded.

Capital deployment is more uneven. The last six months had $189.3M versus $384M in the previous six months, down about 51%, mainly because the previous six-month period included GRAIL’s $325M PIPE and Mercy’s $59M Series B. The last 12 months had $573.3M versus $45M in the previous 12 months, up about 12.7x. So the category is accelerating on a 12-month basis, but individual six-month windows are distorted by large financings.

The category read is straightforward: blood-based early cancer detection is investable again, but only for companies with strong evidence, a clear clinical wedge, or platform-level ambition. ClearNote sits in the attractive middle: not as capital-heavy as GRAIL or Harbinger, but much more commercially advanced than a small proof-of-concept liquid biopsy startup.

Evidence noteCategory funding activity is calculated from disclosed financing announcements in the retained blood-based early cancer detection diagnostics set. Time windows use public announcement dates measured as of May 30, 2026. Capital concentration includes real financing events in the category, including public-company style and debt financings where they materially affect available capital. See methodology below.

Q4How strong is the thesis behind ClearNote Health’s Series D?

The thesis behind ClearNote Health’s Series D is strong because it is specific, clinically grounded, and more commercially realistic than broad “detect every cancer early” rhetoric.

The thesis is this: blood-based, multiomic, AI-enabled early cancer detection will commercialize first in high-risk or clinically actionable populations, especially for lethal cancers with weak or no standard screening. ClearNote applies that thesis to pancreatic and ovarian cancer, with pancreatic cancer as the sharpest commercial wedge.

In the last six months, three similar-thesis companies raised financing: ClearNote Health, Harbinger Health, and Cyclomics. Together, they raised roughly $155M. Excluding ClearNote, similar-thesis companies raised roughly $103M. In the last 12 months, four similar-thesis companies raised: ClearNote Health, Harbinger Health, Cyclomics, and Mercy BioAnalytics. Together, they raised roughly $214M, or roughly $162M excluding ClearNote.

In the last 24 months, six similar-thesis companies raised: ClearNote Health, Harbinger Health, Cyclomics, Mercy BioAnalytics, OXcan, and PrognomiQ. Together, they raised roughly $259M, or roughly $207M excluding ClearNote. ClearNote ranks third in this thesis set by round size. Harbinger ranks first with $100M, or about 38.6% of thesis-set capital. Mercy BioAnalytics ranks second with $59M, or about 22.8%. ClearNote ranks third with $52M, or about 20.1%.

One whole section is dedicated to this point in our latest market report.

Mercy BioAnalytics is the closest comp. It raised a $59M Series B in September 2025 to advance extracellular-vesicle liquid biopsy for earlier cancer detection, starting with ovarian and lung cancers. The overlap with ClearNote is strong: blood-based molecular detection, lethal cancers, ovarian cancer exposure, and a focus on earlier detection where late diagnosis drives poor outcomes.

Harbinger Health is the bigger, flashier comp. It announced $100M in financing in April 2026 around its blood-based multi-cancer detection strategy. The similarity is high because Harbinger also combines blood-based cancer detection, platform logic, prospective validation, and commercial-readiness framing. The difference is that Harbinger looks broader, while ClearNote looks more tactically focused on high-risk pancreatic cancer.

PrognomiQ and OXcan are also relevant but narrower lung-cancer comps. PrognomiQ raised a $34M Series D in November 2024 for multiomics blood-based early lung cancer detection. OXcan raised an $11M Series A in January 2025 for proteomics and AI-enabled early lung cancer detection. Both support the same broad movement toward blood-based molecular screening, but neither matches ClearNote’s pancreatic and ovarian positioning as closely as Mercy.

Investor activity around this thesis is accelerating. Similar-thesis deal count increased from one deal in the previous six months to three deals in the last six months. It increased from two deals in the previous 12 months to four deals in the last 12 months. Capital deployment also increased, from $59M in the previous six months to roughly $155M in the last six months, and from $45M in the previous 12 months to roughly $214M in the last 12 months.

Across other sectors, there were two strong analogue rounds in the last 24 months: Circular Genomics and Cleerly. Circular Genomics raised a $15M Series A in December 2025 to advance circular RNA blood biomarkers for early Alzheimer’s detection. That is the strongest non-cancer analogue because it uses a blood-based molecular signal to detect disease earlier, validate clinically, and prepare for commercial deployment. Cleerly raised a $106M Series C extension in December 2024 to scale AI-enabled coronary CT analysis for earlier heart disease detection. It is less similar because it is imaging-based, but the commercialization pattern is close: noninvasive detection, earlier intervention, clinical evidence, and payer/provider adoption.

The broader market context supports ClearNote’s thesis but also makes it more demanding. Blood-based screening is gaining institutional acceptance, but broad MCED remains under pressure because payers and clinicians want proof of clinical utility, not just interesting detection rates. That is why ClearNote’s high-risk strategy is so important. A narrowly defined, high-unmet-need population is easier to justify than a general-population screening claim.

ClearNote’s thesis is not guaranteed, but it is one of the more intelligent versions of early cancer detection. The company is not trying to win the category by being the broadest. It is trying to win by being more clinically usable. In a market full of ambitious cancer-screening promises, that is a sharper and more investable position.

Evidence noteThesis strength is assessed from alignment between the round narrative, ClearNote’s product wedge, validation data, regulatory and study milestones, and comparable financings. The similar-thesis set includes companies whose round narrative is more than 80% aligned with the retained thesis, rather than every company in liquid biopsy or oncology diagnostics. See methodology below.

In our biotechnology market deck, you will find everything you need to understand the market

§

Methodology, Sources & Disclosure

All timing comparisons in this note are measured as of May 30, 2026. Funding-round time windows refer to announcement dates, not legal close dates, unless a close date is separately disclosed.

The retained investment thesis behind ClearNote Health’s Series D is that blood-based, multiomic, AI-enabled early cancer detection will commercialize first in high-risk or clinically actionable populations, especially for lethal cancers with weak or no standard screening. This thesis was retained because ClearNote’s clearest product wedge is Avantect Pancreatic Cancer Test for elevated-risk groups, and because the round followed clinical validation, regulatory progress, institutional study selection, and commercial leadership hires.

The category used for market-activity analysis is blood-based early cancer detection diagnostics. It includes companies developing noninvasive blood tests that use biomarkers such as cfDNA, methylation, epigenomics, fragmentomics, proteomics, extracellular vesicles, glycans, or other molecular signals, often interpreted with AI or machine learning, to detect cancer before conventional diagnosis or before symptoms become obvious.

The direct competitor set used for funding comparisons includes GRAIL, Freenome, Exact Sciences, Harbinger Health, DELFI Diagnostics, Mercy BioAnalytics, PrognomiQ, and Oxford Cancer Analytics. Competitor funding rankings include only private or venture-backed companies with comparable disclosed financing data, so Exact Sciences is excluded from startup-style cumulative funding rankings as a public-company outlier. Guardant Health is discussed qualitatively but excluded from the direct competitor set because Shield is focused on colorectal cancer screening, where established screening alternatives already exist.

The similar-thesis set includes companies whose round narrative is more than 80% aligned with ClearNote’s retained thesis. The retained peer rounds are Harbinger Health’s $100M financing, Mercy BioAnalytics’ $59M Series B, ClearNote Health’s $52M Series D, PrognomiQ’s $34M Series D, Cyclomics’ recent financing, and Oxford Cancer Analytics’ $11M Series A. Cross-sector analogues include Circular Genomics’ $15M Series A and Cleerly’s $106M Series C extension, although Cleerly is imaging-based rather than blood-based.

Category capital concentration is calculated by summing disclosed funding rounds in the retained category set over the relevant period. When round amounts are disclosed as “more than” a given figure, concentration figures are treated as approximate and use the disclosed lower bound. Public-company style financings and debt financings are included in category-capital totals when they represent real capital entering the retained market category, but are separated where they would distort private startup funding comparisons.

We selected these sources because they come either from direct company announcements, which are the primary source for funding, product, regulatory, clinical, and leadership milestones, or from tier-1 / authoritative publications, which provide independent validation, sector context, and comparable market signals: ClearNote Health Series D announcement, ClearNote Health ASCO validation data announcement, ClearNote Health enhanced Avantect performance announcement, ClearNote Health leadership expansion announcement, ClearNote Health SAFE-D enrollment announcement, ClearNote Health UKCA approval announcement, ClearNote Health NCI Vanguard selection announcement, WSJ Pro Venture Capital coverage of ClearNote’s Series D, Freenome $254M financing announcement, Mercy BioAnalytics $59M Series B announcement, Harbinger Health Resolve and financing announcement, PrognomiQ $34M Series D announcement, Oxford Cancer Analytics $11M Series A announcement, DELFI Diagnostics Series B announcement, Exact Sciences Cancerguard launch announcement, Bluestar Genomics $70M Series C announcement, Bluestar Genomics rebrand to ClearNote Health announcement, Silverwood Partners June 2025 transaction review, Form D tracker for Bluestar Genomics / ClearNote Health.

We are not affiliated with ClearNote Health, its investors, or the named comparable companies. No payment, consideration, or commitment of future business has been received from ClearNote Health, its investors, or any named comparable company in connection with this note. Nothing herein constitutes investment advice or an offer to transact in any security.